Status: Recruiting
Autologous CAR-T Cell Therapy for Refractory and Relapsing Ulcerative Colitis: A Single-Center Exploratory Study
A Single-Center, Open-Label, Single-Arm Exploratory Clinical Study on the Use of Autologous CAR-T Cell Therapy Injection for the Treatment of Refractory and Relapsing Ulcerative Colitis: A Preliminary Exploration of 12-Week Clinical Remission with Autologous CAR-T Cell Injection in Refractory and Relapsing Ulcerative Colitis.
Participants needed: 12
Trial details
Phase: Early Phase 1Age: 18-60Biological sex: AllType: InterventionalSponsor: Hebei Senlang Biotechnology Inc., Ltd.Updated: Feb 27, 2026Locations: 1
Eligibility criteria
The subject or guardian must provide voluntary informed consent; [+4]
Women who are pregnant or lactating; [+9]